ATR Earnings

ATR reported its earnings on 2026-02-05, showcasing a revenue of 962.74M against an estimate of 896.66M, resulting in a 7.37% surprise. The EPS was 1.25, surpassing the expected 1.24 by 0.81% . The stock experienced a 8.33% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ATR's earnings announcement on 2026-02-05, the stock price moved by 8.33% on the day of the release. Over the subsequent five days, it saw a % change. Historically, ATR's stock price tends to shift by an average of -0.34% in the 10 days leading up to earnings and +2.04% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate ATR’s annual revenue to reach 933.72M, while the EPS is projected at 1.21. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ATR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ATR's stock price typically moves by -0.34% in the 10 days before its earnings and +2.04% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 1.21 and revenue of 933.72M.

The earnings call summary and Q&A indicate positive sentiment: strong injectables demand, beauty and closures recovery, and strategic acquisitions. Despite emergency medicine headwinds, overall margins are expected to improve. The $600 million buyback authorization and $100 million cost savings initiatives are additional positives. Although management avoided specific guidance, the overall outlook remains optimistic, justifying a positive stock price reaction.